Oral / Subcutaneous · GLP-1 / GLP-2 dual
PG-102 / RT-114
5 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
5
Ongoing
4
Recruiting
1
Completed
1
Sites
16
Countries
2
Endpoints
50
Composite endpoints
2
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
2
Phase 2
3
Trials by status
Not yet recruiting
2
Recruiting
1
Active, not recruiting
1
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
27
Glycemic / diabetes
12
Weight & body composition
11
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
2
Treatment-emergent AEs (any)Safety/PK
2
Body weight, absolute change (kg)Weight
1
Body weight, % changeWeight
1
Fasting glucose, changeGlycemic
1
Immunogenicity (ADA)Safety/PK
1
CmaxSafety/PK
1
AUC₀-∞Safety/PK
1
TmaxSafety/PK
1
BMI, changeWeight
1
Waist circumference, changeWeight
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
5 of 5
Showing 1-5 of 5 trials